# data[].attributes.body
Medagaget (August 2019). Barostim Neo Neuromodulation Device for Heart Failure Wins FDA Approval. Retrieved from https://www.medgadget.com/2019/08/barostim-neo-neuromodulation-device-for-heart-failure-wins-fda-approval.html.

# data[].attributes.body
September 30th, 2019

# data[].attributes.body
Abraham (Arranger)
-I chose Abraham as a team member because people strong in the arranger ability are organized and can arrange resources to achieve maximal productivity. I need someone on my team who is gifted in organization and efficiency.

Chelsea (Command)
-People strong in the command ability can typically take control of a situation and make clear decisions. I chose to include Chelsea in my team because, on occasion, I have a hard time making a final decision when attempting to implement a project.

Daniel (Discipline)
-I chose Daniel for my team because those strong in the discipline theme are very orderly and maintain structure. I thrive in structured environments, but sometimes team projects can become chaotic and disordered. I need someone on my team who can create order and help the group maintain a highly productive and structured environment.

Faith (Futuristic)
-I need someone on my team who is a visionary; someone who can keep the group inspired and not lose sight of the final goal. Those who are strong in the futuristic theme  are inspired by the future and they have the ability to inspire others about the future.

Matthew (Maximizer)
-People who possess the maximizer strength have the ability to stimulate personal and group excellence. Matthew has a strength that could really tie my team together.

# data[].attributes.body
-Learner
-Deliberative
-Analytical
-Competition
-Restorative

# data[].attributes.body
The recent FDA approval of the Barostim Neo neuromodulator device, has grabbed my attention because I frequently work with patients who suffer from heart failure. In my experience, there is a very large group of patients who could potentially benefit from this device. Many patients with heart failure and a reduced ejection fraction are seeking a "quick fix" and, while this device is not intended to be a stand alone solution to a chronic problem, it has the capacity to improve the quality of life in patients with heart failure with an ejections fraction of 35% or less. Many patients are overwhelmed by the thought of adding another medication to their daily heart failure regimen; this device could be the next step for patients who have mostly maxed out their options for pharmacologic therapy. I also like that this product gives the clinician has the ability to remotely monitor the device and view the patient's hemodynamic profile. Based on my interaction with patients, living with heart failure with a reduced ejection fraction can result in every day activities becoming overwhelming and exhausting; thus far, this product has shown promising results in improving the quality of life in this particular patient population.

# data[].attributes.body
-Invasive; implantation procedure involves some risks
-Not indicated for patients with carotid stenosis greater than 50%.
-requires office based monitoring
-requires eventual device battery changes
-efficacy my be impacted by patient compliance with follow up appointments.

# data[].attributes.body
-Therapeutic benefit for NYHA class II and III heart failure (HF).
-LVEF improvement as early as six months after implantation of device.
-BNP improvement seen  in most patients.
-Offers the following to HF patients: improved quality of life, decrease HF symptoms, increase functional capacity.
-Demonstrates a reduction in HF related hospitalizations.
-improvement in HF parameters.
-FDA clearance.
-Non pharmacologic treatment option.

# data[].attributes.body
A Minnesota- based company known as CVRx has created a game changing product for patients with heart failure: the Barostim Neo Neuromodulation device. The device was created with the intent to provide a non pharmacological treatment options for patients with a diagnosis of heart failure and an ejection fraction less than or equal to 35%. The device is similar in appearance to a pacemaker (it includes a single carotid sinus lead and an implantable pulse generator), and is implanted in the chest wall. The device has the capacity to stimulate the carotid artery, which stimulates the baroreceptors that control the cardiac activity (Medegaget, 2019). The device is connected to a wireless programmer system, which enables the provider to customize the therapy delivered by the product based on the patient's specific needs.